Overview

Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.

Status:
Unknown status
Trial end date:
2019-04-11
Target enrollment:
Participant gender:
Summary
Apatinib second line treatment for Advanced osteosarcoma and soft tissue sarcomas ,openting ,single center, one-armed clinical study.
Phase:
Phase 2
Details
Lead Sponsor:
Henan Cancer Hospital
Collaborator:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Apatinib